DISSECTION 2.0

Study information page DISSECTION 2.0 - Switzerland-wide study investigating the value of pelvic lymph node removal in the context of prostatectomy for prostate cancer

The DISSECTION 2.0 study investigates the comparison between removal and non-removal of the pelvic lymph nodes in radical prostatectomy for prostate cancer. This platform provides information for patients treated within the framework of DISSECTION 2.0.

Center Investigator

30dd8fc1-f4af-4c4c-a45d-7d281f3c65b5

Prof. Cyrill Rentsch

Leitender Arzt

Urologie

Show profile

Sub-Investigator

523c1533-7151-40eb-8ce5-a88d8e217f15

Dr. Christian Engesser

Oberarzt

Urologie

Show profile

Study Nurse

0c42e07d-e162-420b-985c-f9a3d9fea2af

Heike Püschel

Leitende Study Nurse

Urologie

Show profile

557ee2e5-b18b-46b0-8aa1-558287e1ebf7

Maeve Dreher

Study Nurse

Urologie

Show profile

Phone +41 61 55 654 77

E-mail: dissection-study@usb.ch

Patientenrekrutierung

Dissection
Dissection Kurve

Information for patients

This study is investigating whether removal of the pelvic lymph nodes has an effect on the development of prostate cancer.

The current standard for radical prostatectomy, i.e. the surgical removal of the prostate, is the simultaneous removal of the pelvic lymph nodes if there is an increased risk of cancer metastases in the lymph nodes.

However, it is still unclear whether the removal of the pelvic lymph nodes actually represents an advantage in terms of the course of the disease.

The aim is to gain reliable insights into the possible therapeutic benefit of removing the pelvic lymph nodes at the same time. In addition, the data collected will be used to create models to determine who is most likely to benefit from the procedure.

Participation in the study is voluntary and lasts up to 15 years, similar to cancer aftercare. The study patient must adhere to the schedule and all instructions given by the investigator.

Before participation, various routine examinations are carried out, including possibly a computer tomography (CT), a magnetic resonance tomography (MRT) or a positron emission tomography (PET-CT) of the whole body. In addition, the prostate-specific antigen (PSA value) is determined and a physical examination is carried out.

After inclusion in the study, the patient is randomly assigned to one of two treatment groups.

Standard treatment/control group: A prostatectomy with removal of the pelvic lymph nodes is performed.

Experimental group: Prostate removal without removal of the pelvic lymph nodes.

After the operation, follow-up checks are carried out after 3 months, 6 months, 1 year and then annually until the 10th year and a final check-up after 15 years. A follow-up check is also carried out if a relapse is suspected. This corresponds to the standard follow-up schedule for your cancer.

The PSA value is evaluated, as well as questions to record side effects/complications and quality of life.

The study patient must inform the investigator if their state of health changes, e.g. if they feel worse or if new symptoms occur. This also applies if the patient wishes to terminate the study prematurely.

DISSECTION 2.0 is a multicenter, national study. The University Hospital Basel is the coordinating center.

The following centers in Switzerland are already participating in the study. Further centers will follow.

  • University Hospital Basel
  • Cantonal Hospital Baselland
  • University Hospital Zurich